Literature DB >> 20717980

Viewing FOP through rosi-colored glasses.

Frederick S Kaplan1, Robert J Pignolo, Eileen M Shore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20717980      PMCID： PMC4957688          DOI： 10.1002/jbmr.214

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN： 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  9 in total

1.  A CONTRIBUTION TO THE STUDY OF MYOSITIS OSSIFICANS PROGRESSIVA.

Authors:  J Rosenstirn
Journal:  Ann Surg       Date:  1918-12       Impact factor: 12.969

2.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

Review 3.  The effect of thiazolidinediones on BMD and osteoporosis.

Authors:  Allyson K McDonough; Richard S Rosenthal; Xu Cao; Kenneth G Saag
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-09

4.  Rosiglitazone therapy is associated with major clinical improvements in a patient with fibrodysplasia ossificans progressiva.

Authors:  Davide Gatti; Ombretta Viapiana; Maurizio Rossini; Adami Silvano
Journal:  J Bone Miner Res       Date:  2010-06       Impact factor: 6.741

5.  Use of thiazolidinediones and fracture risk.

Authors:  Christian Meier; Marius E Kraenzlin; Michael Bodmer; Susan S Jick; Hershel Jick; Christoph R Meier
Journal:  Arch Intern Med       Date:  2008-04-28

6.  A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

Authors:  N D Oakes; C J Kennedy; A B Jenkins; D R Laybutt; D J Chisholm; E W Kraegen
Journal:  Diabetes       Date:  1994-10       Impact factor: 9.461

7.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

Review 8.  Applications of small molecule BMP inhibitors in physiology and disease.

Authors:  Charles C Hong; Paul B Yu
Journal:  Cytokine Growth Factor Rev       Date:  2009-11-14       Impact factor: 7.638

Review 9.  Fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Martine Le Merrer; David L Glaser; Robert J Pignolo; Robert E Goldsby; Joseph A Kitterman; Jay Groppe; Eileen M Shore
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.